Mileshkin L, et al. - Through a single-arm, open-label trial of anastrozole, 1 mg/d in 82 patients with estrogen (ER) and/or progesterone (PR) positive hormonal therapy naive metastatic endometrial cancer, the researchers reported the results of a phase 2 trial of anastrozole in order to determine clinical benefit rate with aromatase inhibitors and the effect of treatment on quality of life (QOL) in endometrial cancer. In 82 evaluable patients, the clinical benefit rate at 3 months was 44%. Treatment was well endured. Two months including improvements in several QOL domains like in emotional functioning, cognitive functioning, fatigue, and global health status were observed in patients who had a clinical advantage at 3 months in comparison to those with progressive disease. Hence, the clinical advantage was seen in 44% of patients with ER/PR positive metastatic endometrial cancer and was correlated with an improvement in QOL, even though the objective response rate to anastrozole was relatively flat.